

BioMed X Innovation Center

Fact Sheet

The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics and consumer care. These interdisciplinary project teams are conducting groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, under the guidance of experienced mentors from academia and industry while expanding their scientific network and receiving an entrepreneurship and leadership training. Each team is typically partnered by a corporate pharma or biotech partner of BioMed X. After a fully funded project term, successful projects are either internalized into the development pipeline of the respective pharma or biotech partner or spun off into an independent startup company.

BioMed X's facilities are based in Heidelberg, Germany and are embedded within the Life Science Campus Neuenheimer Feld, surrounded by renowned research institutes such as University of Heidelberg, German Cancer Research Center, National Center for Tumor Diseases, European Molecular Biology Laboratory, Center for Molecular Biology, Heidelberg University Hospital with 44 specialized clinical departments, and approximately 100 large and small life science companies.

HQ and facilities in Germany: Im Neuenheimer Feld 583 and 515
69120 Heidelberg
Germany

Phone: +49 6221 426 110
E-Mail: info@bio.mx
www.bio.mx

Employees: > 60

Diversity: approx. 45 % male, 55 % female
> 20 nationalities

Facilities: 1,500 sqm laboratory and office space

Founding year: 2013

Sponsors: AbbVie
Boehringer Ingelheim
Johnson & Johnson
Merck KGaA
Roche

Research teams: 9

Research areas: oncology, immunology, neuroscience, diagnostics, consumer care
(bio.mx/research-teams)

New innovation model ([Betz & Tidona 2015: Nature Biotechnology 33, pp. 20-21](#)):

1. World-wide publication of a very tough early R&D challenge (provided by pharma / biotech partner, on average BioMed X receives 200-500 project proposals from 30-60 countries per challenge);
2. Selection and invitation of the 15 best candidates to a 5-day boot camp in Heidelberg (purpose: heterogeneous team building, mentorship, conversion of outstanding ideas into well-designed project proposals);
3. Selection and relocation of 3-5 winning candidates for a 2-4 year fellowship at the BioMed X Innovation Center in Heidelberg (pharma / biotech partner financially supports its BioMed X research teams including overhead and management fee, all generated IP is transferred to pharma / biotech partner against payment of a pre-negotiated exit fee at the end of the project term).

Value Proposition for pharma / biotech partners:

- Access to outstanding international academic talents who would normally not apply for a job at big pharma / biotech;
- Cost-effective global crowdsourcing of original project proposals (vs world-wide business development efforts);
- Cross-pollination of international top talents via relocation to a joint open innovation lab in Heidelberg;
- Access to academic research infrastructure and the BioRN Network in Heidelberg, one of the strongest biomedical innovation hubs in Europe (e.g. University of Heidelberg, German Cancer Research Center, National Center for Tumor Diseases, European Molecular Biology Laboratory, Center for Molecular Biology, Heidelberg University Hospital with 44 specialized clinical departments, around 100 large and small life science companies);
- Ownership of generated intellectual property (no royalties on sales);
- Novel combination of crowdsourcing, open innovation and incubator approaches.